Skin Cancer

SKIN CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma

More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?

Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
Industry-Funded Study Suggests There Is No Association Between TCI Use and Increased Skin Cancer Risk in Atopic Dermatitis

Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
Skin Toxicity Program Can Positively Address EGFR Inhibitor-Related Skin Toxicities

Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
irAEs Linked to Ipilimumab Should Not Preclude Subsequent Anti–PD-1 Therapy

This retrospective study suggests that patients with prior ipilimumab-related adverse events related can safely retry anti–PD-1 therapy.

VIDEO SERIES

Recent Advances in Melanoma Therapy

Targeted Treatments and Immunotherapies for Melanoma

Tailoring Treatments in Melanoma

Drug Resistance in Melanoma

Affordability of Melanoma Care

Melanoma: Treatment-induced Toxicity

Immunotherapy: A Decade of Improvements in Melanoma

Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

Melanoma: Checkpoints in the Pipeline

Targeting Therapy for Melanoma Subtypes

Melanoma: Targetable Genes in the Pipeline

Clinical Trials in Melanoma

SKIN CANCER NEWS

Combining PD-1 blockade with PAK4 inhibitors could boost the number of patients helped by the therapy.

Risk of Melanoma Measured in Mutation Burden of Skin Cells

October 26, 2020

Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.

Prior History of SCC Could Be a Red Flag for Development of SCC in the Setting of CLL

August 27, 2020

FDA: Small Risk of Skin Cancer With Hydrochlorothiazide Use

August 24, 2020

Measuring an adult patient's height.

Study Investigates Association Between Height and Risk of Invasive Melanoma

June 18, 2020

Racial minorities are poorly represented in genomic research databases, raising important questions

Racial Differences Seen in Time to Treatment for Melanoma

June 8, 2020

Next post in Skin Cancer

More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.

Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma